EPHA2 and breast cancer: For example, in the context of MDA-MB-231 breast cancer cell lines, the engagement of the EA1.2 monoclonal antibody with the extracellular domain of EphA2 initiates receptor phosphorylation, culminating in its subsequent degradation [100].